Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Allergan Inc., solvency ratios (quarterly data)
Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Allergan Inc. debt to equity ratio improved from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Allergan Inc. debt to capital ratio improved from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Allergan Inc. debt to assets ratio improved from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Allergan Inc. financial leverage ratio increased from Q2 2014 to Q3 2014 but then decreased significantly from Q3 2014 to Q4 2014. |
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Allergan Inc. interest coverage ratio deteriorated from Q2 2014 to Q3 2014 but then improved from Q3 2014 to Q4 2014 exceeding Q2 2014 level. |
Debt to Equity
Allergan Inc., debt to equity calculation (quarterly data)
| Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Notes payable | 72,100) | 55,800) | 60,900) | 61,100) | 55,600) | 37,200) | 51,600) | 57,200) | 48,800) | 40,700) | 42,400) | 87,700) | 83,900) | 78,800) | 76,100) | 36,300) | 28,100) | 18,500) | 13,100) | 17,900) | ||||||
| Convertible notes | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 648,900) | 642,500) | 636,000) | 629,700) | —) | ||||||
| Long-term debt, excluding current maturities | 2,085,300) | 2,088,600) | 2,091,800) | 2,095,100) | 2,098,300) | 2,101,500) | 2,104,600) | 2,107,700) | 1,512,400) | 1,515,500) | 1,514,900) | 1,514,700) | 1,515,400) | 1,516,200) | 1,510,300) | 1,529,500) | 1,534,200) | 1,546,000) | 888,700) | 877,800) | ||||||
| Long-term convertible notes | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 623,500) | ||||||
| Total debt | 2,157,400) | 2,144,400) | 2,152,700) | 2,156,200) | 2,153,900) | 2,138,700) | 2,156,200) | 2,164,900) | 1,561,200) | 1,556,200) | 1,557,300) | 1,602,400) | 1,599,300) | 1,595,000) | 1,586,400) | 2,214,700) | 2,204,800) | 2,200,500) | 1,531,500) | 1,519,200) | ||||||
| Total Allergan, Inc. stockholders’ equity | 7,753,000) | 7,110,700) | 6,786,000) | 6,617,900) | 6,463,200) | 6,085,900) | 5,721,900) | 5,337,100) | 5,837,100) | 5,569,600) | 5,438,800) | 5,458,600) | 5,309,600) | 5,105,700) | 4,963,900) | 4,865,700) | 4,757,700) | 4,459,500) | 5,088,000) | 4,944,800) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to equity1 | 0.28 | 0.30 | 0.32 | 0.33 | 0.33 | 0.35 | 0.38 | 0.41 | 0.27 | 0.28 | 0.29 | 0.29 | 0.30 | 0.31 | 0.32 | 0.46 | 0.46 | 0.49 | 0.30 | 0.31 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Amgen Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Bristol-Myers Squibb Co. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Danaher Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Eli Lilly & Co. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Gilead Sciences Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Johnson & Johnson | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Merck & Co. Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Pfizer Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Thermo Fisher Scientific Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Zoetis Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).
1 Q4 2014 Calculation
Debt to equity = Total debt ÷ Total Allergan, Inc. stockholders’ equity
= 2,157,400 ÷ 7,753,000 = 0.28
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Allergan Inc. debt to equity ratio improved from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014. |
Debt to Capital
Allergan Inc., debt to capital calculation (quarterly data)
| Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Notes payable | 72,100) | 55,800) | 60,900) | 61,100) | 55,600) | 37,200) | 51,600) | 57,200) | 48,800) | 40,700) | 42,400) | 87,700) | 83,900) | 78,800) | 76,100) | 36,300) | 28,100) | 18,500) | 13,100) | 17,900) | ||||||
| Convertible notes | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 648,900) | 642,500) | 636,000) | 629,700) | —) | ||||||
| Long-term debt, excluding current maturities | 2,085,300) | 2,088,600) | 2,091,800) | 2,095,100) | 2,098,300) | 2,101,500) | 2,104,600) | 2,107,700) | 1,512,400) | 1,515,500) | 1,514,900) | 1,514,700) | 1,515,400) | 1,516,200) | 1,510,300) | 1,529,500) | 1,534,200) | 1,546,000) | 888,700) | 877,800) | ||||||
| Long-term convertible notes | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 623,500) | ||||||
| Total debt | 2,157,400) | 2,144,400) | 2,152,700) | 2,156,200) | 2,153,900) | 2,138,700) | 2,156,200) | 2,164,900) | 1,561,200) | 1,556,200) | 1,557,300) | 1,602,400) | 1,599,300) | 1,595,000) | 1,586,400) | 2,214,700) | 2,204,800) | 2,200,500) | 1,531,500) | 1,519,200) | ||||||
| Total Allergan, Inc. stockholders’ equity | 7,753,000) | 7,110,700) | 6,786,000) | 6,617,900) | 6,463,200) | 6,085,900) | 5,721,900) | 5,337,100) | 5,837,100) | 5,569,600) | 5,438,800) | 5,458,600) | 5,309,600) | 5,105,700) | 4,963,900) | 4,865,700) | 4,757,700) | 4,459,500) | 5,088,000) | 4,944,800) | ||||||
| Total capital | 9,910,400) | 9,255,100) | 8,938,700) | 8,774,100) | 8,617,100) | 8,224,600) | 7,878,100) | 7,502,000) | 7,398,300) | 7,125,800) | 6,996,100) | 7,061,000) | 6,908,900) | 6,700,700) | 6,550,300) | 7,080,400) | 6,962,500) | 6,660,000) | 6,619,500) | 6,464,000) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to capital1 | 0.22 | 0.23 | 0.24 | 0.25 | 0.25 | 0.26 | 0.27 | 0.29 | 0.21 | 0.22 | 0.22 | 0.23 | 0.23 | 0.24 | 0.24 | 0.31 | 0.32 | 0.33 | 0.23 | 0.24 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Amgen Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Bristol-Myers Squibb Co. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Danaher Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Eli Lilly & Co. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Gilead Sciences Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Johnson & Johnson | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Merck & Co. Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Pfizer Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Thermo Fisher Scientific Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Zoetis Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).
1 Q4 2014 Calculation
Debt to capital = Total debt ÷ Total capital
= 2,157,400 ÷ 9,910,400 = 0.22
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Allergan Inc. debt to capital ratio improved from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014. |
Debt to Assets
Allergan Inc., debt to assets calculation (quarterly data)
| Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Notes payable | 72,100) | 55,800) | 60,900) | 61,100) | 55,600) | 37,200) | 51,600) | 57,200) | 48,800) | 40,700) | 42,400) | 87,700) | 83,900) | 78,800) | 76,100) | 36,300) | 28,100) | 18,500) | 13,100) | 17,900) | ||||||
| Convertible notes | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 648,900) | 642,500) | 636,000) | 629,700) | —) | ||||||
| Long-term debt, excluding current maturities | 2,085,300) | 2,088,600) | 2,091,800) | 2,095,100) | 2,098,300) | 2,101,500) | 2,104,600) | 2,107,700) | 1,512,400) | 1,515,500) | 1,514,900) | 1,514,700) | 1,515,400) | 1,516,200) | 1,510,300) | 1,529,500) | 1,534,200) | 1,546,000) | 888,700) | 877,800) | ||||||
| Long-term convertible notes | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 623,500) | ||||||
| Total debt | 2,157,400) | 2,144,400) | 2,152,700) | 2,156,200) | 2,153,900) | 2,138,700) | 2,156,200) | 2,164,900) | 1,561,200) | 1,556,200) | 1,557,300) | 1,602,400) | 1,599,300) | 1,595,000) | 1,586,400) | 2,214,700) | 2,204,800) | 2,200,500) | 1,531,500) | 1,519,200) | ||||||
| Total assets | 12,415,700) | 11,645,800) | 10,990,800) | 10,720,200) | 10,574,300) | 10,144,600) | 9,675,000) | 9,250,500) | 9,179,300) | 8,910,900) | 8,673,400) | 8,684,200) | 8,508,600) | 8,184,000) | 7,879,600) | 8,370,700) | 8,308,100) | 8,540,100) | 7,787,600) | 7,628,400) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to assets1 | 0.17 | 0.18 | 0.20 | 0.20 | 0.20 | 0.21 | 0.22 | 0.23 | 0.17 | 0.17 | 0.18 | 0.18 | 0.19 | 0.19 | 0.20 | 0.26 | 0.27 | 0.26 | 0.20 | 0.20 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Amgen Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Bristol-Myers Squibb Co. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Danaher Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Eli Lilly & Co. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Gilead Sciences Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Johnson & Johnson | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Merck & Co. Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Pfizer Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Thermo Fisher Scientific Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Zoetis Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).
1 Q4 2014 Calculation
Debt to assets = Total debt ÷ Total assets
= 2,157,400 ÷ 12,415,700 = 0.17
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Allergan Inc. debt to assets ratio improved from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014. |
Financial Leverage
Allergan Inc., financial leverage calculation (quarterly data)
| Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Total assets | 12,415,700) | 11,645,800) | 10,990,800) | 10,720,200) | 10,574,300) | 10,144,600) | 9,675,000) | 9,250,500) | 9,179,300) | 8,910,900) | 8,673,400) | 8,684,200) | 8,508,600) | 8,184,000) | 7,879,600) | 8,370,700) | 8,308,100) | 8,540,100) | 7,787,600) | 7,628,400) | ||||||
| Total Allergan, Inc. stockholders’ equity | 7,753,000) | 7,110,700) | 6,786,000) | 6,617,900) | 6,463,200) | 6,085,900) | 5,721,900) | 5,337,100) | 5,837,100) | 5,569,600) | 5,438,800) | 5,458,600) | 5,309,600) | 5,105,700) | 4,963,900) | 4,865,700) | 4,757,700) | 4,459,500) | 5,088,000) | 4,944,800) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Financial leverage1 | 1.60 | 1.64 | 1.62 | 1.62 | 1.64 | 1.67 | 1.69 | 1.73 | 1.57 | 1.60 | 1.59 | 1.59 | 1.60 | 1.60 | 1.59 | 1.72 | 1.75 | 1.92 | 1.53 | 1.54 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Amgen Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Bristol-Myers Squibb Co. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Danaher Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Eli Lilly & Co. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Gilead Sciences Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Johnson & Johnson | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Merck & Co. Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Pfizer Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Thermo Fisher Scientific Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Zoetis Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).
1 Q4 2014 Calculation
Financial leverage = Total assets ÷ Total Allergan, Inc. stockholders’ equity
= 12,415,700 ÷ 7,753,000 = 1.60
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Allergan Inc. financial leverage ratio increased from Q2 2014 to Q3 2014 but then decreased significantly from Q3 2014 to Q4 2014. |
Interest Coverage
Allergan Inc., interest coverage calculation (quarterly data)
| Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Net earnings (loss) attributable to Allergan, Inc. | 537,200) | 312,500) | 417,200) | 257,300) | 312,900) | 299,800) | 359,900) | 12,500) | 324,200) | 249,400) | 295,400) | 229,800) | 279,800) | 249,800) | 246,600) | 158,300) | 263,100) | (670,500) | 240,100) | 167,900) | ||||||
| Add: Net income attributable to noncontrolling interest | 1,900) | 900) | 1,200) | 600) | (600) | 1,000) | 1,300) | 1,900) | 1,000) | 1,200) | 1,000) | 500) | (100) | 1,200) | 2,000) | 500) | —) | 1,800) | 1,400) | 1,100) | ||||||
| Less: Discontinued operations | (3,500) | 300) | —) | (600) | (300) | (32,100) | 7,200) | (258,600) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | ||||||
| Add: Income tax expense | 91,300) | 106,300) | 156,000) | 103,100) | 128,400) | 123,900) | 132,400) | 73,600) | 124,100) | 80,200) | 132,000) | 94,500) | 104,000) | 105,800) | 95,400) | 56,400) | 69,900) | (59,000) | 92,000) | 63,000) | ||||||
| Add: Interest expense | 15,600) | 18,400) | 19,700) | 15,700) | 18,200) | 19,400) | 20,000) | 17,400) | 14,800) | 15,900) | 17,100) | 15,800) | 16,700) | 15,200) | 15,200) | 24,700) | 27,800) | 20,400) | 13,900) | 16,600) | ||||||
| Earnings before interest and tax (EBIT) | 649,500) | 437,800) | 594,100) | 377,300) | 459,200) | 476,200) | 506,400) | 364,000) | 464,100) | 346,700) | 445,500) | 340,600) | 400,400) | 372,000) | 359,200) | 239,900) | 360,800) | (707,300) | 347,400) | 248,600) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Interest coverage1 | 29.66 | 25.95 | 26.12 | 24.82 | 24.08 | 25.29 | 24.69 | 24.85 | 25.11 | 23.41 | 24.05 | 23.41 | 19.10 | 16.07 | 2.87 | 2.77 | 3.17 | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Interest Coverage, Competitors2 | ||||||||||||||||||||||||||
| Amgen Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Danaher Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Gilead Sciences Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Johnson & Johnson | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Thermo Fisher Scientific Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Zoetis Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).
1 Q4 2014 Calculation
Interest coverage
= (EBITQ4 2014
+ EBITQ3 2014
+ EBITQ2 2014
+ EBITQ1 2014)
÷ (Interest expenseQ4 2014
+ Interest expenseQ3 2014
+ Interest expenseQ2 2014
+ Interest expenseQ1 2014)
= (649,500 + 437,800 + 594,100 + 377,300)
÷ (15,600 + 18,400 + 19,700 + 15,700)
= 29.66
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Allergan Inc. interest coverage ratio deteriorated from Q2 2014 to Q3 2014 but then improved from Q3 2014 to Q4 2014 exceeding Q2 2014 level. |